CAD 0.96
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2024 | - CAD | 0.0% |
2023 | - CAD | -100.0% |
2022 | 164 Thousand CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | -100.0% |
2012 | 421 Thousand CAD | -20.27% |
2011 | 528 Thousand CAD | -32.31% |
2010 | 780 Thousand CAD | -9.09% |
2009 | 858 Thousand CAD | 87.34% |
2008 | 458 Thousand CAD | -15.03% |
2007 | 539 Thousand CAD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 0.0% |
2024 Q3 | - CAD | 0.0% |
2024 Q4 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 FY | - CAD | -100.0% |
2023 Q1 | 254 Thousand CAD | 54.88% |
2023 Q2 | - CAD | -100.0% |
2022 Q4 | 164 Thousand CAD | 0.0% |
2022 FY | 164 Thousand CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 FY | - CAD | -100.0% |
2013 Q1 | 305 Thousand CAD | -27.55% |
2013 Q2 | - CAD | -100.0% |
2013 Q3 | - CAD | 0.0% |
2012 Q3 | 456 Thousand CAD | -9.7% |
2012 Q2 | 505 Thousand CAD | 18.82% |
2012 FY | 421 Thousand CAD | -20.27% |
2012 Q4 | 421 Thousand CAD | -7.68% |
2012 Q1 | 425 Thousand CAD | -19.51% |
2011 FY | 528 Thousand CAD | -32.31% |
2011 Q4 | 528 Thousand CAD | 0.0% |
2010 FY | 780 Thousand CAD | -9.09% |
2009 FY | 858 Thousand CAD | 87.34% |
2008 FY | 458 Thousand CAD | -15.03% |
2007 FY | 539 Thousand CAD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Appili Therapeutics Inc. | - CAD | NaN% |
Eupraxia Pharmaceuticals Inc. | 1.00 CAD | 100.0% |
Microbix Biosystems Inc. | 5.75 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | -583 Thousand CAD | 100.0% |
Oncolytics Biotech Inc. | - CAD | NaN% |
Sernova Corp. | - CAD | NaN% |